# CONVERT

Source: https://onco.cc/trials/convert/  
OnCo record `convert` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Settled the radiotherapy schedule debate in limited-stage disease: neither schedule was superior, so twice-daily 45 Gy remains standard and once-daily is an acceptable alternative.

## Summary

CONVERT, trial NCT00433563 sponsored by Cancer Research UK and the EORTC and reported in 2017, settled the radiotherapy schedule debate in limited-stage small-cell lung cancer: neither schedule was superior, so twice-daily 45 Gy remains standard and once-daily 66 Gy is an acceptable alternative. It randomised 547 patients to twice-daily or once-daily thoracic radiotherapy with concurrent cisplatin and etoposide, was designed to show superiority of the once-daily schedule and did not, with similar toxicity and both arms outperforming historical controls. OnCo links it to small-cell lung cancer, modern external beam radiotherapy, the limited-stage term and Corinne Faivre-Finn. Because it was not a non-inferiority design, whether once-daily treatment is truly equivalent rather than merely not proven superior is the open question.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-09-07
- Registry id: NCT00433563
- Phase: 3
- Setting: Limited-stage SCLC: twice-daily 45 Gy vs once-daily 66 Gy thoracic radiotherapy with concurrent cisplatin-etoposide
- Sponsor: Cancer Research UK / EORTC
- Enrolled: 547
- Result: No significant difference; twice-daily 45 Gy remains standard.
- Outcomes: Overall survival: Twice-daily 45 Gy 30 months vs Once-daily 66 Gy 25 months, HR 1.18

## Sources

- ClinicalTrials.gov NCT00433563: https://clinicaltrials.gov/study/NCT00433563

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- companies: [EORTC](https://onco.cc/companies/curie-nki-eortc/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/), [The Christie NHS Foundation Trust](https://onco.cc/institutions/the-christie/)
- terms: [Control arm and comparator (investigator's choice)](https://onco.cc/terms/control-arm/), [External and synthetic control arms](https://onco.cc/terms/external-control-arm/), [Limited-stage vs extensive-stage (small-cell lung cancer)](https://onco.cc/terms/limited-extensive-stage/), [Non-inferiority margin and equivalence trials](https://onco.cc/terms/non-inferiority-margin/), [Non-inferiority trial](https://onco.cc/terms/non-inferiority/), [Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover](https://onco.cc/terms/trial-failure-modes/)
- trials: [CHART](https://onco.cc/trials/chart-lung/), [Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy](https://onco.cc/trials/turrisi-intergroup-0096/)
- people: [Corinne Faivre-Finn](https://onco.cc/people/corinne-faivre-finn/)
- key papers: [Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial](https://onco.cc/key-papers/paper-convert-lancet-oncol-2017/), [Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial](https://onco.cc/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/)
- roadmaps: [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/convert.json